merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Undercutting the price while offering a safer, regulated alternative</answer>
<question_number>2</question_number>
<answer>By providing a direct-to-consumer option that bypasses third-party telehealth companies</answer>
<question_number>3</question_number>
<answer>Lack of FDA oversight and potential safety issues</answer>
<question_number>4</question_number>
<answer>To compete directly with lower-cost alternatives and regain control over the market</answer>
<question_number>5</question_number>
<answer>Compounding pharmacies can legally produce alternatives when a drug is listed as in shortage</answer>
<question_number>6</question_number>
<answer>Reflects a move towards transparent pricing and cutting out intermediaries</answer>
<question_number>7</question_number>
<answer>Increased risk for older patients due to potential muscle mass loss</answer>
<question_number>8</question_number>
<answer>By positioning its vials as a safer, regulated option</answer>
<question_number>9</question_number>
<answer>Being listed on the FDA's shortage list</answer>
<question_number>10</question_number>
<answer>By pricing competition</answer>